As published on owkin.com, June 2026. Checked by usedby on Oct 9, 2026.
What happened
Sanofi is working with Owkin on a multi-year collaboration to co-develop AI agents for drug research and development. The agents will be deployed through Owkin's K Pro AI Scientist, under a license.
Summary written by usedby from the source page, in English. The figures are those of Owkin and Sanofi, not ours.
During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built for Sanofi.
Across Sanofi, we are continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle. By implementing purpose-built agentic systems into our workflows, we aim to empower our teams to operate with greater speed, depth, and confidence as we continue to work to deliver transformative outcomes for patients.
What the story claims, and what we checked
What we compared with the page.
- The passage quoted aboveCheckedCopied word for word from the page, near the name of Sanofi.
- The publication dateCheckedRead from the page’s own metadata, never guessed.
- Sanofi uses OwkinCheckedConfirmed line.
- The result itselfNot checkedWe quote it; we did not measure it.
More stories
Same company, same tool or same industry.
